radoncreview_org @radoncreview

Our mission is to create the most comprehensively updated Rad Onc reference and to make it available for free, forever, for all. RadOnc.org Joined September 2019

Tweets

899
Followers

4K
Following

619
Likes

1K

Dr. Nina Niu Sanford @NiuSanford

2 days ago

RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource. GI highlights below. #ASTRO25

radoncreview_org @radoncreview

2 days ago

RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource. GI highlights below. #ASTRO25 https://t.co/nfKnkFp96n

1 32 73 15K 51

3 21 71 10K 36

Download Image

radoncreview_org @radoncreview

2 days ago

The latest #ASTRO25 study dump now brings us to over 2,000 studies logged since May 2020. Happy studying and treating, and thank you for being part of this community! 🔗 bit.ly/RoROnDeck

radoncreview_org @radoncreview

2 days ago

The latest #ASTRO25 study dump now brings us to over 2,000 studies logged since May 2020. Happy studying and treating, and thank you for being part of this community! 🔗 bit.ly/RoROnDeck https://t.co/w2mBejAla9

1 32 73 15K 51

0 2 1 845 0

Download Image

radoncreview_org @radoncreview

2 days ago

Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25

1 32 73 15K 51

Matthew Culbert, MD @culbert_md

2 months ago

Check out the new updates to #RadOncCalc and @RadoncTables available now on all platforms (iOS, Android, web) Rad Onc Tables IOS ➡️ is.gd/tnqpTT Android ➡️ is.gd/dzc9xH Rad Onc Calc IOS ➡️ is.gd/txHOue Android ➡️ is.gd/HzIP5x

3 16 43 5K 5

Download Video

radoncreview_org @radoncreview

5 months ago

Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! ncbi.nlm.nih.gov/pubmed/32316464

0 2 3 792 1

Download Image

radoncreview_org @radoncreview

5 months ago

Rituximab does not decrease transformation to DLBCL. Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude. DLBCL-free survival is a meaningful endpoint for patients. Teamwork is key! 🤝 #LYMSM sciencedirect.com/science/articl…

Ajay Major, MD, MBA @majorajay

5 months ago

1 2 17 4K 6

Download Image

1 5 4 2K 2

Download Image

Jeff Ryckman @jryckman3

7 months ago

Seeing some logical fallacies in this debate. It not logically sound to assume that patients who progress on NAC-ICI wouldn’t have responded to upfront chemoradiotherapy.

Jeff Ryckman @jryckman3

7 months ago

Seeing some logical fallacies in this debate. It not logically sound to assume that patients who progress on NAC-ICI wouldn’t have responded to upfront chemoradiotherapy.

2 3 17 6K 4

Download Image

0 2 5 2K 2

radoncreview_org @radoncreview

7 months ago

@NiuSanford @freddyeescorcia Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper! This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! pubmed.ncbi.nlm.nih.gov/25899219/

1 3 8 580 4

Download Image

radoncreview_org @radoncreview

7 months ago

Math checks out with absolute dose! HCC is a rather radiosensitive tumor. Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control. For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of…

James Good @drjamesgood

7 months ago

0 1 8 4K 0

0 10 26 4K 10

Download Image

David S Chang @dschan02

7 months ago

@NiuSanford @radoncreview @HCCLIVEConf I've never understood Y90 dosimetry. The prescription dose in Gy is so high, ~10x EBRT and ~3x LDR Brachy, despite Y90's half-life being much shorter than prostate LDR isotopes. Why does intravascular therapy require such a massive dose? Does any biologically relevant volume…

0 2 6 513 0

radoncreview_org @radoncreview

7 months ago

Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC

1 2 2 4K 0

radoncreview_org @radoncreview

7 months ago

Is this the most important question? @HCCLIVEConf #HCC 🧩

radoncreview_org @radoncreview

7 months ago

Is this the most important question? @HCCLIVEConf #HCC 🧩

1 2 2 4K 0

0 1 1 875 0

Neil Newman @nbn426

7 months ago

Until we get clear data - the story for larger tumors and especially MVI is that min dose does matter … I have seen tumor thrombus progress into confluence for example Until dosimetry is clear to interpret ( such as EYE90) along with positive phase 3 trial - onus is on y90…

radoncreview_org @radoncreview

7 months ago

1 2 2 4K 0

1 2 12 2K 0

James Good @drjamesgood

7 months ago

@NiuSanford @radoncreview @HCCLIVEConf Nope. You need 10% of that, in five fractions. ALARA.

0 1 8 4K 0

Dr. Nina Niu Sanford @NiuSanford

7 months ago

@radoncreview @HCCLIVEConf Thanks Jeff, I think it highlights a good pt that Riad touches upon. Y90 and SBRT dose are measured differently though both in Gy...you don't need 400 Gy to whole tumor in HCC - it's a radiosensitive histology.